Stony Brook Heart Institute’s Center for Advanced Lipid Management has achieved a historic global milestone, becoming the first center in the world to administer a commercial dose of plozasiran, the ...
Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...
Researchers identify a shared RNA-protein interaction that could lead to broad-spectrum antiviral treatments for enteroviruses ...
Sean Ryder, professor at UMass Chan Medical School, has written a book to delve the mysteries of ribonucleic acid as a tool to fight diseases. Messenger ribonucleic acid, or mRNA, is in the public ...
Arrowhead Pharmaceuticals, Inc. today announced that it is scheduled to participate in the following upcoming events: Obesity KOL Webinar ? ARO-INHBE and ARO-ALK7 Interim Clinical Data ? January 6, ...
TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...
TipRanks on MSN
Sirnaomics completes phase I trial of cancer drug STP707 and files clinical report with FDA
Sirnaomics Ltd. ( ($HK:2257) ) has issued an announcement. Sirnaomics Ltd. has announced that its subsidiary Sirnaomics, Inc. has completed a ...
Alnylam Pharmaceuticals is expanding its Norton facility with a $250 million investment to enhance RNAi therapeutic ...
A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...
Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...
With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...
With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback